INMED PHARMACEUTICALS INC. Employee Benefits and Share-based Compensation
INMED PHARMACEUTICALS INC. (INM) reported Employee Benefits and Share-based Compensation of $278.15 thousand for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-29.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2023-09-29
- INMED PHARMACEUTICALS INC. employee benefits and share-based compensation for the quarter ending 2023-06-30 was $40.48K, a 77.12% decline year-over-year.
- INMED PHARMACEUTICALS INC. employee benefits and share-based compensation for the quarter ending 2023-03-31 was $50.36K, a 74.19% decline year-over-year.
- INMED PHARMACEUTICALS INC. employee benefits and share-based compensation for the quarter ending 2022-12-31 was $70.64K, a 67.11% decline year-over-year.
- INMED PHARMACEUTICALS INC. employee benefits and share-based compensation for the quarter ending 2022-09-30 was $116.68K, a 4.98% increase year-over-year.
- INMED PHARMACEUTICALS INC. employee benefits and share-based compensation for fiscal 2023 was $278.15K, a 60.14% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. employee benefits and share-based compensation for fiscal 2022 was $697.89K, a 14.37% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. employee benefits and share-based compensation for fiscal 2021 was $610.19K, a 38.64% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. employee benefits and share-based compensation for fiscal 2020 was $994.40K.
| Period end | Employee Benefits and Share-based Compensation 3 month | Employee Benefits and Share-based Compensation 6 month | Employee Benefits and Share-based Compensation 9 month | Employee Benefits and Share-based Compensation 12 month |
|---|---|---|---|---|
| 2023-06-30 | $40.48K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $90.84K derived: sum of 2 quarters · filed 2023-09-29 | $161.47K derived: sum of 3 quarters · filed 2023-09-29 | $278.15K 10-K · filed 2023-09-29 |
| 2023-03-31 | $50.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $121.00K derived: sum of 2 quarters · filed 2023-05-15 | $237.68K 10-Q · filed 2023-05-15 | $414.56K derived: sum of 4 quarters · filed 2023-09-29 |
| 2022-12-31 | $70.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $187.32K 10-Q · filed 2023-02-17 | $364.21K derived: sum of 3 quarters · filed 2023-09-29 | $559.29K derived: sum of 4 quarters · filed 2023-09-29 |
| 2022-09-30 | $116.68K 10-Q · filed 2022-11-14 | $293.57K derived: sum of 2 quarters · filed 2023-09-29 | $488.65K derived: sum of 3 quarters · filed 2023-09-29 | $703.43K derived: sum of 4 quarters · filed 2023-09-29 |
| 2022-06-30 | $176.89K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $371.97K derived: sum of 2 quarters · filed 2023-09-29 | $586.75K derived: sum of 3 quarters · filed 2023-09-29 | $697.89K 10-K · filed 2023-09-29 |
| 2022-03-31 | $195.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $409.86K derived: sum of 2 quarters · filed 2023-05-15 | $521.01K 10-Q · filed 2023-05-15 | $741.86K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $214.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $325.92K 10-Q · filed 2023-02-17 | $546.77K derived: sum of 3 quarters · filed 2023-02-17 | $754.07K derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-09-30 | $111.14K 10-Q · filed 2022-11-14 | $331.99K derived: sum of 2 quarters · filed 2022-11-14 | $539.29K derived: sum of 3 quarters · filed 2022-11-14 | $635.93K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $220.85K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $428.15K derived: sum of 2 quarters · filed 2022-09-23 | $524.79K derived: sum of 3 quarters · filed 2022-09-23 | $610.19K 10-K · filed 2022-09-23 |
| 2021-03-31 | $207.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $303.94K derived: sum of 2 quarters · filed 2022-05-13 | $389.34K 10-Q · filed 2022-05-13 | $545.44K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $96.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $182.04K 10-Q · filed 2022-02-14 | $338.14K derived: sum of 3 quarters · filed 2022-02-14 | $542.01K derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $85.41K 10-Q · filed 2021-11-10 | $241.50K derived: sum of 2 quarters · filed 2021-11-10 | $445.37K derived: sum of 3 quarters · filed 2021-11-10 | $729.33K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $156.10K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $359.97K derived: sum of 2 quarters · filed 2021-09-24 | $643.92K derived: sum of 3 quarters · filed 2021-09-24 | $994.40K 10-K · filed 2021-09-24 |
| 2020-03-31 | $203.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | $487.82K derived: sum of 2 quarters · filed 2021-05-13 | $838.30K 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $283.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $634.43K 10-Q · filed 2021-02-11 | ||
| 2019-09-30 | $350.48K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |